← Back to Search

Validation and Implementation Design of an Epic Systems 30-day Unplanned Readmission Risk Model

N/A
Waitlist Available
Led By Donna Williams, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 30
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a software tool that helps doctors identify patients who are likely to need to come back to the hospital after being discharged. The tool calculates a risk score and suggests additional care services for high-risk patients. The goal is to reduce unplanned readmissions by providing extra support to those who need it most.

Eligible Conditions
  • Unplanned Hospital Readmissions
  • High-risk patients for unplanned readmission

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 30
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 30 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of transitional and supportive care services (TSC) referrals by providers in the Control group
Number of transitional and supportive care services (TSC) referrals by providers in the Control group - Care Plus
Number of transitional and supportive care services (TSC) referrals by providers in the Control group - Faith Health
+12 more
Secondary study objectives
30 day Readmission Rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: intervention group (IG)Experimental Treatment1 Intervention
The IG will consist of placing the Epic 30-day unplanned readmission risk score in the story board of providers - If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board
Group II: control group (CG)Active Control1 Intervention
The CG will have the same transitional and supportive care services (TSC) orders available to them; however, they will not have the risk of readmission score present in their workflow
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Epic 30-day unplanned readmission risk score
2023
N/A
~70

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,403 Previous Clinical Trials
2,477,867 Total Patients Enrolled
Donna Williams, MDPrincipal InvestigatorWake Forest University Health Sciences

Media Library

Epic 30-day unplanned readmission risk score Clinical Trial Eligibility Overview. Trial Name: NCT05413889 — N/A
Unplanned Hospital Readmissions Research Study Groups: intervention group (IG), control group (CG)
Unplanned Hospital Readmissions Clinical Trial 2023: Epic 30-day unplanned readmission risk score Highlights & Side Effects. Trial Name: NCT05413889 — N/A
Epic 30-day unplanned readmission risk score 2023 Treatment Timeline for Medical Study. Trial Name: NCT05413889 — N/A
~24 spots leftby Dec 2025